Introduction to the LUX-Lung 7 head-to-head trial

LUX-Lung 7 is the first global, prospectively randomised head-to-head trial comparing two EGFR targeting agents in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC).

Hear more from experts Dr Kerr, Dr Kato and Dr Melosky.